

Anti-CEACAM5-DM4(Dar4)[Tusamitamab ravtansine]

Product Information


Product Name	Anti-CEACAM5-DM4(Dar4)[Tusamitamab ravtansine]
Storage temp.	Store at +4°C short term. Store at -80°C for 36 months, avoiding freeze/thaw cycles.
Catalog# / Size	GM-87846AB-100 / 100 µg GM-87846AB-1mg / 1 mg

Antibody Information

Expression System	CHO
Purity	> 95% as determined by SDS-PAGE
Aggregation	< 5% as determined by SEC-HPLC
Drug-to-Antibody Ratio (DAR)	3.0-4.0
Endotoxin	<1EU/mg
Sterility	0.22 µm Filtered
Target	CEACAM5
Clone	Tusamitamab ravtansine
Alternative Names	CD66e, CEA
Source/Isotype	Monoclonal Human IgG1, kappa
Application	Positive control of Cytotoxicity Assay
Description	Tusamitamab ravtansine (SAR408701) is a novel antibody-drug conjugate (ADC) targeting CEA (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5, also known as CD66e). The drug specifically binds to CEA-expressing tumor cells through its chimeric monoclonal antibody and is subsequently internalized into the cells, where it releases the conjugated cytotoxic molecule DM4 (ravtansine, a derivative of an anti-microtubule agent). DM4 disrupts microtubule function, blocks mitosis, and induces tumor cell apoptosis. Tusamitamab ravtansine combines the benefits of targeted therapy and chemotherapy, enhancing treatment precision while significantly reducing systemic toxicity and off-target effects.
Formulation	Phosphate-buffered solution, pH 7.2-7.4.


Version:3.1

SDS-PAGE




On SDS-PAGE under reducing (R)/non-reducing(N-R) condition. The purity of the protein is greater than 95%.

SEC-HPLC



The purity of this product is greater than 95% verified by SEC-HPLC.

UV-Vis



The drug-to-antibody ratio (DAR) of this product is 3.63.